Highlights VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-01 pm EDT			5-day change	1st Jan Change
6 ^USD	+1.01%		+19.88%	-35.53%

Apr. 12	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
Apr. 02	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 02	CI
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	Feb. 21	MT
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	Feb. 21	CI
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	23-10-31	CI
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	23-10-26	CI
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs	23-09-28	CI
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study	23-09-27	CI
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	23-09-26	CI
Vaccinex to Implement 1-for-15 Reverse Stock Split	23-09-22	MT
Vaccinex, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Earnings Flash (VCNX) VACCINEX Reports Q1 Revenue $550,000	23-05-15	MT
Vaccinex, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Vaccinex, Inc. Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab	23-04-25	CI
Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-31	CI
Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23-03-21	CI
Vaccinex, Inc. Reports KEYNOTE B-84 Has Reached Targeted Enrollment for Pre-Planned Interim Analysis	23-03-09	CI
Vaccinex, Inc. Announces First Patient Dosed with Anti-Ccr8 Antibody Licensed to Surface Oncology	23-01-09	CI
Earnings Flash (VCNX) VACCINEX Reports Q3 Revenue $50,000	22-11-14	MT
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights VACCINEXPAR

Equities

VCNX

US9186403013

Highlights

Filters